Welcome to Paid Research Studies


Browse Locations ... United States» ... New Hampshire» ... Concord






  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Rituximab;   Drug: Lenalidomide;   Drug: Rituximab;   Drug: Placebo
    Sponsor:   Celgene Corporation
    Recruiting - verified August 2014

  • Conditions:   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
    Interventions:   Drug: ibrutinib;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: lenalidomide;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Drug: cabozantinib-s-malate;   Drug: sunitinib malate;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
    Interventions:   Drug: cisplatin;   Drug: etoposide;   Drug: paclitaxel;   Drug: carboplatin;   Drug: erlotinib hydrochloride;   Drug: crizotinib;   Radiation: intensity-modulated radiation therapy;   Radiation: 3-dimensional conformal radiation therapy;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Recurrent Adult Brain Tumor
    Interventions:   Biological: anti-endoglin monoclonal antibody TRC105;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: Fulvestrant;   Drug: Ganetespib
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting - verified August 2014

  • Conditions:   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone;   Procedure: Autologous Stem Cell Transplant
    Sponsors:   Dana-Farber Cancer Institute;   Paul G. Richardson, MD;   Celgene Corporation;   Millennium Pharmaceuticals, Inc.;   Massachusetts General Hospital;   Cape Cod Healthcare;   Beth Israel Deaconess Medical Center;   Emory University;   University of Michigan;   Fox Chase Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Fred Hutchinson Cancer Research Center;   Barbara Ann Karmanos Cancer Institute;   Duke University;   University of California, San Francisco;   University of Chicago;   M.D. Anderson Cancer Center;   UNC Lineberger Comprehensive Cancer Center;   Roswell Park Cancer Institute;   Stanford University;   University of Mississippi Medical Center;   Mount Sinai School of Medicine;   Wake Forest Baptist Health;   University of Arizona;   OHSU Knight Cancer Institute;   Eastern Maine Medical Center;   University of California, San Diego;   University of Alabama at Birmingham;   University of Pittsburgh;   Ochsner Health System;   University of Texas Southwestern Medical Center;   State University of New York - Downstate Medical Center;   Newton-Wellesley Hospital;   Baylor College of Medicine;   Beckman Research Institute;   University of Florida;   North Shore Long Island Jewish Health System;   H. Lee Moffitt Cancer Center and Research Institute;   Vanderbilt University;   Ohio State University;   Huntsman Cancer Institute;   Columbia University
    Recruiting - verified August 2014

  • Condition:   Ductal Breast Carcinoma in Situ
    Interventions:   Biological: trastuzumab;   Radiation: whole breast irradiation;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014